Royalty Management Hldgs Bolsa (NASDAQ: RMCO)

Últimas noticias sobre Royalty Management Hldgs (NASDAQ:RMCO) Bolsa

Royalty Management Hldgs

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

Royalty Management Holding Corporation - Class A Common Stock

Royalty Management Holding Corp

Royalty Management Holding Corporation - Warrant

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $13 to $10.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $10

Stifel analyst Jim Duffy maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Hold and lowers the price target from $240 to $226.

Stifel Maintains Hold on Dick's Sporting Goods, Lowers Price Target to $226

HC Wainwright &amp; Co. analyst Yi Chen maintains LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and raises the price target from $12 to $14.

LFMD

HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $14

Guidance

ONDS

Ondas Sees FY25 Revenue Of $25M Vs. $33.44M Est.

Ondas Posts Q4 Net Loss Of $10.3M Versus $14.1M In Q4 FY23

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $17 to $15.

ZYXI

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $15

Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) reported quarterly sales of $7.19 million which beat the analyst consensus estimate of $5.75 million by 25.08 percent. This is a 44.97 percent increase over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Ondas Holdings Q4 Sales $7.19M Beat $5.75M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

Reiteration

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) with a Outperform and maintains $2 price target.

GROV

Telsey Advisory Group Maintains Outperform on Grove Collaborative Hldgs, Maintains $2 Price Target

Sprinklr Sees FY26 Revenues Between $821.5M-$823.5M Vs. $819.73M Estimate, With Adjusted EPS Of $0.38-$0.39 Vs. $0.38 Estimate

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Sprinklr Sees Q1 Revenues Between $201.5M-$202.5M Vs. $200.41M Estimate, With Adjusted EPS Of $0.10 Vs. $0.08 Estimate

The chairperson of Alibaba Group Holding ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Joseph Tsai acknowledged that everyone around the world is concerned about the ongoing tariff battle between the economic powerhouses of the world.
What Happened: While speaking at CNBC&#8217;s event Converge Live, in Singapore, Tsai responded to a question on tariff imposition by the Donald Trump administration and said that &#8220;Everyone is concerned about tariffs.&#8221;
He highlighted that the Chinese multinational technology company sells $50 billion worth of American products on its platform to Chinese consumers every year. On the other hand, about $30 billion worth of European products are also sold annually.
"I think the Trump administration will want to have more American companies doing business in China and making money there," he said, adding that it was ultimately between the global leaders to meet and decide on the future course of these protectionist policies.
Furthermore, he suggested if Trump&#8217;s wider tariff approach was just a bargaining chip, there was still a likelihood of seeing specific tariffs on Chinese electric vehicles. Tsai added that it could be a move to safeguard the American auto industry from potential competition.
See Also: <a href="https://www.benzinga.com/25/03/44269729/debt-over-equity-billionaire-howard-marks-endorses-credit-investments-amid-shifting-investor-focus-and-market-correction">Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: &#8216;Yields Implies Higher Returns From Credit Than The S&amp;P 500&#8217;</a>
Why It Matters: On Tuesday afternoon, President Trump unexpectedly reversed his decision to double tariffs on Canadian steel and aluminum to 50%, just hours after announcing the increase. The abrupt policy change, which rattled financial markets, followed Canada&#8217;s withdrawal of plans for a 25% surcharge on electricity.
Additionally, as Trump&#8217;s tariffs on steel and aluminum imports go into effect, the European Union announced on Wednesday that it will retaliate by imposing levies of 26 billion euros or $28.33 billion on U.S. goods beginning in April.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 0.73% to $560.00, and the QQQ also advanced 0.83% to $475.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44245897/billionaire-investor-ron-baron-reacts-to-nasdaq-sp-selloff-the-stock-prices-cant-believe-how-cheap-they-are" target="_blank" rel="noreferrer noopener">Billionaire Investor Ron Baron Reacts To Nasdaq, S&amp;P Selloff: ‘The Stock Prices…Can't Believe How Cheap They Are'</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Global

Economics

Markets

BABA

Alibaba's Joseph Tsai Says 'Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $75 to $50.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $50

United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) reported quarterly earnings of $0.01 per share. This is a 100.72 percent increase over losses of $(1.38) per share from the same period last year. The company reported $134.81 million in sales this quarter. This is a 15.39 percent increase over sales of $116.83 million the same period last year.

United Homes Gr Q4 EPS $0.01 Up From $(1.38) YoY, Sales $134.81M Up From $116.83M YoY

Barrington Research analyst Vincent Colicchio maintains Barrett Business Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) with a Outperform and maintains $45 price target.

BBSI

Barrington Research Maintains Outperform on Barrett Business Services, Maintains $45 Price Target

OPRX

OptimizeRx Sees FY25 Adjusted EBITDA Of At Least $12M

Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.60) by 16.67 percent. This is a 47.06 percent decrease over losses of $(0.34) per share from the same period last year.

SGMT

Sagimet Biosciences Q4 2024 GAAP EPS $(0.50) Beats $(0.60) Estimate

OptimizeRx Sees FY25 Revenue Of At Least $100M Vs. $99.646M Est.

Needham analyst Matt Dezort reiterates Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) from Hold to Hold.

Comments

Royalty Management Hldgs

Noticias

Últimas noticias sobre Royalty Management Hldgs (NASDAQ:RMCO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL